MAIA Biotechnology (NYSE American: MAIA) launches digital asset treasury plan

Rhea-AI Filing Summary

MAIA Biotechnology filed a current report describing a new treasury strategy that adds digital assets to how it manages its corporate funds. The company announced a plan to hold a portion of its treasury in a diversified portfolio focused on top-tier cryptocurrency assets, as detailed in an accompanying press release.

This move formally introduces exposure to cryptocurrencies at the corporate level, in addition to traditional cash and financial assets. The filing emphasizes that statements about this strategy and its future impact are forward-looking and subject to risks and uncertainties, including broader business, regulatory, and market factors affecting the company’s operations and product development.

Insights

Corporate treasury and risk management analyst

MAIA adds crypto exposure to its treasury, introducing new strategic and risk considerations.

MAIA Biotechnology introduces a digital asset treasury strategy focused on top-tier cryptocurrency assets. This means part of its corporate treasury may now be held in cryptocurrencies rather than solely in traditional instruments. The move is framed through an official press release incorporated by reference into the report.

The disclosure does not quantify allocation size, specific coins, or timing, but standard forward-looking language highlights risks and uncertainties. Crypto holdings can expose a company to price volatility, evolving regulation, and custody or operational risks, alongside any potential upside. The actual impact on MAIA will depend on how much of its treasury it allocates, how it manages risk, and future market and regulatory developments.

false 0001878313 0001878313 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2025

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 7, 2025, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing the launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated October 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 7, 2025

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

FAQ

What did MAIA (MAIA) disclose in this 8-K filing?

MAIA Biotechnology reported that it has launched a new digital asset treasury strategy, under which it plans to hold a portion of its treasury in top-tier cryptocurrency assets, as described in an attached press release.

How is MAIA Biotechnology changing its treasury strategy with cryptocurrencies?

The company announced a digital asset treasury strategy that will focus on top-tier cryptocurrency assets, meaning it plans to include selected cryptocurrencies as part of its overall approach to managing corporate funds.

Where can investors find more details on MAIAs crypto treasury approach?

Additional details are provided in the press release dated October 7, 2025, which is attached to the report as Exhibit 99.1 and incorporated by reference.

Does MAIA Biotechnology discuss risks related to its new digital asset strategy?

Yes. The company includes forward-looking statements language noting that future results are subject to risks, uncertainties, and factors beyond its control, and it cautions that actual outcomes may differ materially from expectations.

Is this MAIA 8-K filing about earnings or financial results?

No. The filing is categorized as an Other Events report and focuses on announcing the launch of a digital asset treasury strategy, rather than reporting earnings or detailed financial results.

What exhibit is included with MAIAs October 7, 2025 8-K?

The filing includes Exhibit 99.1, a press release dated October 7, 2025 describing the digital asset treasury strategy, and Exhibit 104, the cover page interactive data file embedded in Inline XBRL.